Which hedge funds own VRTX? VERTEX PHARMACEUTICALS INC, Q2 2026 13F holders
75 tracked hedge funds disclosed a position in VRTX (VERTEX PHARMACEUTICALS INC) in their Q2 2026 13F filings, worth $3.4bn in total. The largest holder by portfolio weight is Tri Locum Partners LP at 12.3% of its book. 21 opened a new position this quarter: CTC Alternative Strategies, Ltd., Ishara Investments LP, Ardsley Advisory Partners LP, Quantitative Investment Management, LLC. 22 exited: Superstring Capital Management LP, Arrowpoint Investment Partners (Singapore) Pte. Ltd., Twin Tree Management, LP.
- 75
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 21
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 22
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $50.7m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $62.3m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $3.4bn
- Combined value Sum of the holders' reported positions in the security.
- 6.1%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Superstring Capital Management LP | 3.5% | $4.9m |
| Arrowpoint Investment Partners (Singapore) Pte. Ltd. | 2.2% | $1.5m |
| Twin Tree Management, LP | 0.7% | $3.5m |
| Diadema Partners LP | 0.7% | $1.7m |
| Oxford Asset Management LLP | 0.5% | $1.1m |
| ADAR1 Capital Management, LLC | 0.4% | $6.7m |
| Caxton Associates LLP | 0.4% | $16.1m |
| Lecap Asset Management Ltd | 0.3% | $673k |
| Persistent Asset Partners Ltd | 0.2% | $419k |
| Campbell & CO Investment Adviser LLC | 0.1% | $2.5m |
| Diametric Capital, LP | 0.1% | $455k |
| Stevens Capital Management LP | 0.1% | $709k |
| AlphaGrep UK Ltd | 0.1% | $346k |
| ExodusPoint Capital Management, LP | 0.10% | $10.0m |
| EntryPoint Capital, LLC | 0.07% | $234k |
| Trexquant Investment LP | 0.05% | $6.8m |
| Centiva Capital, LP | 0.04% | $959k |
| Gsa Capital Partners LLP | 0.04% | $701k |
| Patton Fund Management, Inc. | 0.04% | $235k |
| Quantbot Technologies LP | 0.01% | $248k |
| Magnetar Financial LLC | 0.01% | $741k |
| Qube Research & Technologies Ltd | 0.0% | $1.8m |
Ownership over time
Who discovered VRTX first? Beta
The run: Q1 2005 → Q4 2015, ×13
| RA Capital Management, L.P. high conviction | Q1 2008 | – | +5.7 pts |
| Sivik Global Healthcare LLC | Q3 2015 | – | +5.1 pts |
| Zweig-DiMenna Associates LLC | Q4 2014 | – | +0.4 pts |
| Atika Capital Management LLC | Q3 2014 | – | +0.4 pts |
| Sphera Funds Management Ltd. | Q3 2014 | – | +0.3 pts |
| Tudor Investment Corp ET AL | Q4 2008 | 0.1% | +0.3 pts |
| Viking Global Investors LP | Q2 2003 | – | 0.0 pts |
| Canyon Capital Advisors LLC | Q2 2015 | – | −0.7 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.